Search Results - "Lobo, Maurice"

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival by Mandalá, Mario, Larkin, James, Ascierto, Paolo A, Del Vecchio, Michele, Gogas, Helen, Cowey, C Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey

“…BackgroundSeveral therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to…”
Get full text

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial by Ascierto, Paolo A, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M, Dalle, Stephane, Cowey, C Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O, Maio, Michele, Middleton, Mark R, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A, Millward, Michael, Khushalani, Nikhil I, Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James, Weber, Jeffrey

“…Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant…”
Get full text

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial by Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V.

“…Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate…”
Get full text

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 by Larkin, James, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance Fernandez, Ana M, Dalle, Stéphane, Cowey, Charles Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Middleton, Mark R, Lutzky, Jose, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew G, Fecher, Leslie A, Millward, Michael, Nathan, Paul D, Khushalani, Nikhil I, Queirolo, Paola, Ritchings, Corey, Lobo, Maurice, Askelson, Margarita, Tang, Hao, Dolfi, Sonia, Ascierto, Paolo A, Weber, Jeffrey

“…In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus…”
Get full text

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials by Weber, Jeffrey S, Middleton, Mark R, Yates, Georgia, Sharpe, Daniel J, Kurt, Murat, Lobo, Maurice, Moshyk, Andriy, Vanderpuye-Orgle, Jacqueline, Mohr, Peter

“…Standard-of-care treatments for patients with resected stage III/IV melanoma include the immuno-oncology (IO) agents nivolumab (NIVO) and ipilimumab (IPI)…”
Get full text

Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data by Weber, Jeffrey S., Gogas, Helen, Sun, Xiaowu, Yip, Christine, Taylor, Fiona, Braverman, Julia, Lobo, Maurice, Thakkar, Pratik K., Moshyk, Andriy, Larkin, James, Ascierto, Paolo Antonio

“…Abstract only 9574 Background: In CheckMate 238, NIVO 3 mg/kg vs ipilimumab 10 mg/kg showed significantly longer recurrence-free survival and a lower rate of…”
Get full text

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria by Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A., Mandalá, Mario

“…Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer…”
Get full text

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 by Dummer, Reinhard, Corrie, Pippa, Gutzmer, Ralf, Meniawy, Tarek M, Del Vecchio, Michele, Lebbé, Céleste, Guida, Michele, Dutriaux, Caroline, Dreno, Brigitte, Meyer, Nicolas, Ferrucci, Pier Francesco, Dalle, Stéphane, Khattak, Muhammad Adnan, Grob, Jean-Jacques, Briscoe, Karen, Larkin, James, Mansard, Sandrine, Lesimple, Thierry, Guidoboni, Massimo, Sabatini, Silvia, Richtig, Erika, Herbst, Rudolf, Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A, Maio, Michele

“…To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety…”
Get full text

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K) by Long, Georgina V., Kirkwood, John M. M., Hoeller, Christoph, Grob, Jean-Jacques, Weber, Jeffrey S., Taube, Janis M., Mohr, Peter, Van Akkooi, Alexander Christopher Jonathan, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Tenney, Daniel J., Dolfi, Sonia, Tang, Hao, Ritchings, Corey, Lobo, Maurice, Campigotto, Federico, Wang, Wenjia, Gastman, Brian, Del Vecchio, Michele

“…9504 Background: Adjuvant NIVO significantly prolonged recurrence-free survival (RFS) over PBO in stage IIB/C melanoma in the randomized, phase III Checkmate…”
Get full text

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial by Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V.

Get full text

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial by Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V.

Get full text

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238 by Weber, Jeffrey, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M, Dalle, Stephane, Cowey, C Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O, Di Giacomo, Anna Maria, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A, Millward, Michael, Khushalani, Nikhil I, Queirolo, Paola, Long, Georgina V, Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A, Larkin, James

“…In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage…”
Get full text

Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data by Moser, Justin C., Bhatia, Shailender, Amin, Asim, Pavlick, Anna C., Betts, Keith A., Du, Ella Xiaoyan, Poretta, Tayla, Shelley, Karishma, Srinivasan, Swetha, Sakkal, Leon Alan, Palaia, Jennell, Lobo, Maurice, Pe Benito, Melanie, Linton, Joshua A., Chen, Yan, Xu, Churong, Yin, Lei, Sundar, Manasvi, Weber, Jeffrey

“…Objectives Nivolumab is approved as adjuvant therapy for resected stage III/IV melanoma based on the phase 3 CheckMate 238 trial. This analysis compared…”
Get full text

KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC) by Stein, Mark N., Fong, Lawrence, Tutrone, Ronald F, Mega, Anthony E., Lobo, Maurice, Hong, Quan, Haas, Naomi B.

“…Abstract only…”
Get full text

Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238 by Larkin, James, Gogas, Helen, Del Vecchio, Michele, Maio, Michele, Arenberger, Petr, Arance, Ana Maria, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Lewis, Karl D., Mortier, Laurent, Ott, Patrick Alexander, Long, Georgina V., Van Den Eertwegh, Alfonsus, Cowey, C. Lance, Schenker, Michael, Butler, Marcus O., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo Antonio, Weber, Jeffrey S.

“…Abstract only 9569 Background: In the phase 3 CheckMate 238 study, NIVO has demonstrated improved recurrence-free survival (RFS) and distant metastasis-free…”
Get full text

Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511 by Lebbe, Celeste, Meyer, Nicolas, Mortier, Laurent, Marquez-Rodas, Ivan, Robert, Caroline, Rutkowski, Piotr, Butler, Marcus O., Eigentler, Thomas, Menzies, Alexander M., Smylie, Michael, Arance, Ana Maria, Ascierto, Paolo Antonio, Svane, Inge Marie, Ajaz, Mazhar, Khushalani, Nikhil I., Lobo, Maurice, Zoco, Jesus, Pigozzo, Jacopo

“…Abstract only 9516 Background: NIVO 1 mg/kg plus IPI 3 mg/kg (NIVO1 + IPI3) is approved for treatment (tx) of unresectable/adv melanoma, with demonstrated…”
Get full text

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218) by Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, Hogg, David

“…CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy,…”
Get full text

589: THE BENEFIT OF NOREPINEPHRINE INFUSION FOR HEMODYNAMIC SUPPORT FOLLOWING CARDIOPULMONARY ARREST AND RESUSCITATION by Kim, Min Jung, Holland, Bart, Lobo, Maurice, Goss, Deborah

Get full text

An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238) by Mandalà, Mario, Larkin, James M.G., Ascierto, Paolo Antonio, Del Vecchio, Michele, Gogas, Helen, Cowey, C. Lance, Arance Fernandez, ANA Maria, Dalle, Stéphane, Schenker, Michael, Grob, Jean Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus, Di Giacomo, Anna Maria, Middleton, Mark R., Lutzky, Jose, Millward, Michael, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey S.

“…Abstract only 9584 Background: In both previous 18- and 24-month follow-up reports from CheckMate 238, NIVO demonstrated significantly longer recurrence-free…”
Get full text

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K) by Long, Georgina V., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Grabbe, Stephan, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quéreux, Gaëlle, Meniawy, Tarek, Ascierto, Paolo A., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Kirkwood, John M.

“…Patients with resected stage IIB/C melanoma are at high risk of recurrence with outcomes similar to patients with resected stage IIIB disease. Adjuvant NIVO…”
Get full text